106976-25-4

Basic information

• Product Name: 2-(acetylamino)-5-bromo-4-methylbenzoic acid
• Synonyms: 2-(acetylamino)-5-bromo-4-methylbenzoic acid
• CAS NO: 106976-25-4
• Molecular Weight: 272.098
• Mol File: 106976-25-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-(acetylamino)-5-bromo-4-methylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(acetylamino)-5-bromo-4-methylbenzoic acid(106976-25-4)
• EPA Substance Registry System: 2-(acetylamino)-5-bromo-4-methylbenzoic acid(106976-25-4)

Safety Data

• Hazardous Substances Data: 106976-25-4(Hazardous Substances Data)

Upstream product

• 106976-24-3 2-amino-5-bromo-4-methylbenzoic acid 
• 108-24-7 acetic anhydride 
• 106976-23-2 5-bromo-6-methylindoline-2,3-dione 
• 6933-10-4 amino-5-bromo-2-toluene 
• 106987-81-9 4-bromo-3-methylisonitrosoacetanilide 

Downstream Products

• 106976-26-5 2-(acetylamino)-5-bromo-4-methyl-3-nitrobenzoic acid 
• 124340-71-2 7-Methyl-2-phenyl-1H-benzoimidazole-4-carboxylic acid (2-dimethylamino-ethyl)-amide 
• 124340-99-4 2-phenyl-7-methyl-1H-benzimidazole-4-carboxylic acid 
• 106976-27-6 5-bromo-4-methyl-3-nitroanthranilic acid 
• 34545-25-0 2,3-diamino-4-methylbenzoic acid 

Relevant articles and documents

Potential Antitumor Agents. 59. Structure-Activity Relationships for 2-Phenylbenzimidazole-4-carboxamides, a New Class of "Minimal" DNA-Intercalating Agents Which May Not Act via Topoisomerase II

A series of substituted 2-phenylbenzimidazole-4-carboxamides has been synthesized and evaluated for in vitro and in vivo antitumor activity.These compounds represent the logical conclusion to our search for "minimal" DNA-intercalating agents with the lowest possible DNA-binding constants.Such "2-1" tricyclic chromophores, of lower aromaticity than the structurally similar 2-phenylquinolines, have the lowest DNA binding affinity yet seen in the broad series of tricyclic carboxamide intercalating agents.Despite very low in vitro cytotoxicities, several of the compoundshad moderate levels of in vivo antileukemic effects.However, the most interesting aspect of their biological activity was the lack of cross-resistance shown to an amsacrine-resistant P388 cell line, suggesting that these compounds may not express their cytotoxicity via interaction with topoisomerase II.